Migraine Trial, Recruiting (NCT06882122)

Migraine Trial, Recruiting NCT06882122 Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT06882122 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 70 years old
You have been diagnosed with episodic migraine (using standard medical guidelines known as ICHD-3)
You have had between 8 and 14 migraine days per month over the past 3 months
You have never previously been treated with CGRP-targeted migraine medications
You are taking no more than one ongoing migraine prevention medication, and the dose has been stable for at least 3 months

Who may not be able to join:

You have a medical reason why you cannot take the study drug, atogepant (confirm with trial site)
You have a history of serious mental health conditions
You have been diagnosed with other types of headache disorders, apart from occasional tension-type headaches
You have other significant medical conditions that the trial doctor considers important (confirm with trial site)
You have a long-term pain condition that requires ongoing treatment
You have a problem with alcohol or drug misuse
You are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00390382380425

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06882122

Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

Trial contact: 00390382380425

More information: https://clinicaltrials.gov/study/NCT06882122

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 70 years old
You have been diagnosed with episodic migraine (using standard medical guidelines known as ICHD-3)
You have had between 8 and 14 migraine days per month over the past 3 months
You have never previously been treated with CGRP-targeted migraine medications
You are taking no more than one ongoing migraine prevention medication, and the dose has been stable for at least 3 months

Who may not be able to join:

You have a medical reason why you cannot take the study drug, atogepant (confirm with trial site)
You have a history of serious mental health conditions
You have been diagnosed with other types of headache disorders, apart from occasional tension-type headaches
You have other significant medical conditions that the trial doctor considers important (confirm with trial site)
You have a long-term pain condition that requires ongoing treatment
You have a problem with alcohol or drug misuse
You are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS National Neurological Institute "C. Mondino" Foundation

Registry

ClinicalTrials.gov

Start date

1 December 2024

Est. completion

1 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Temporal summation threshold of the RIII reflex (continuos variable); MAGL gene expression (continuos variable)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov